CA
NZ
UK
AU
IND
US
…
Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies, enables discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and Mine, a proprietary IP-protected analytics platform that captures all data for all AlloChem compounds in all CoreX assays. Sharp Therapeutics Corp. is headquartered in Pittsburgh, Pennsylvania.
Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website
A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.
Public disclosures for Sharp Therapeutics Corp. (TSX‑V: SHRX.V) are limited; the company is listed on the TSX Venture Exchange and appears positioned as a therapeutics-focused issuer. Major long-term growth drivers are not well disclosed, though investors may benefit if the company advances clinical programs, secures partnerships or achieves clearer operational and financial transparency.
Principal risks include an uncertain or non-commercialized pipeline, small-cap liquidity and financing risk, and the regulatory and execution risks typical of early-stage biotech companies.
Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.
| Breakdown | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 |
| Income before tax | -3.26M | -3.56M |
| Net income | -3.26M | -3.56M |
| Selling general administrative | 0.35M | 0.43M |
| Reconciled depreciation | 0.10M | 0.11M |
| Operating income | -4.55M | -2.27M |
| Interest expense | 0.17M | 0.17M |
| Net interest income | -0.17M | -0.17M |
| Total revenue | 0.00M | 0.00M |
| Total operating expenses | 4.55M | 2.27M |
| Total other income expense net | 1.46M | -1.12M |
| Net income from continuing ops | -3.26M | -3.56M |
| Breakdown | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 |
| Total assets | 4.55M | 1.55M |
| Total liab | 1.97M | 13.03M |
| Total stockholder equity | 2.58M | -11.48M |
| Other current liab | 0.13M | 1.39M |
| Capital stock | 21.79M | 4.55M |
| Retained earnings | -19.89M | -16.62M |
| Cash | 3.48M | 0.38M |
| Total current liabilities | 0.69M | 7.72M |
| Net debt | - | 6.70M |
| Short long term debt | - | 5.89M |
| Total current assets | 3.52M | 0.43M |
| Long term debt | - | 1.19M |
| Accounts payable | 0.27M | 0.18M |
| Non current assets total | 1.04M | 1.12M |
| Capital lease obligations | 1.32M | 1.34M |
| Breakdown | 2024-12-31 | 2023-12-31 |
|---|---|---|
| Type | yearly | yearly |
| Date | 2024-12-31 | 2023-12-31 |
| Net borrowings | 1.76M | -0.20M |
| Total cash from financing activities | 6.73M | 2.18M |
| Net income | -3.26M | -3.56M |
| Change in cash | 3.10M | 0.21M |
| Begin period cash flow | 0.38M | 0.16M |
| End period cash flow | 3.48M | 0.38M |
| Total cash from operating activities | -3.62M | -1.96M |
| Issuance of capital stock | 4.96M | 2.38M |
| Depreciation | 0.10M | 0.11M |
| Capital expenditures | 0.01M | 0.01M |
| Change in working capital | 0.06M | 0.16M |
| Stock based compensation | 0.01M | 0.03M |
| Other non cash items | -0.79M | 0.18M |
| Free cash flow | -3.63M | -1.97M |
Sector: Healthcare Industry: Biotechnology
|
Stock Name
|
Change
(CAD) |
Price
(CAD) |
Trailing
PE (x) |
Forward
PE (x) |
Price Sales
TTM (x) |
Price to Book Value (x)
|
|---|---|---|---|---|---|---|
| SHRX Sharp Therapeutics Corp. |
- -% |
1.37 | - | - | - | 32.37 |
| NRX NurExone Biologic Inc. |
-0.01 2.00% |
0.49 | - | 6.90 | - | 15.26 |
| MIR MedMira Inc |
- -% |
0.06 | - | - | 223.37 | - |
| TTI Thiogenesis Therapeutics Corp. |
- -% |
0.63 | - | - | - | 15.17 |
| ARCH Arch Biopartners Inc |
-0.03 3.41% |
0.85 | - | - | 197.68 | 6211.54 |
Sharp Therapeutics Corp., a preclinical-stage drug discovery company, develops therapeutics for genetic diseases. The company engages in the development of the CoreX, a suite of biology technologies, enables discovery of compounds that correct the mutational defect; AlloChem, a compound library which binds proteins allosterically; and Mine, a proprietary IP-protected analytics platform that captures all data for all AlloChem compounds in all CoreX assays. Sharp Therapeutics Corp. is headquartered in Pittsburgh, Pennsylvania.
| Name | Title | Year Born |
|---|---|---|
| Dr. Scott F. Sneddon J.D., Ph.D. | CEO, Chief Science Officer & Director | 1963 |
| Mr. Edward Jonasson CA CPA | Chief Financial Officer | 1969 |
| Mr. Lorne Michael Sugarman | Independent Director & Corporate Secretary | 1970 |
| Mr. Marcel P. Bruchez Ph.D. | Scientific Co-Founder & CTO | NA |
| Dr. Alan S. Waggoner Ph.D. | Scientific Co-Founder and Chief Architect | NA |
Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.
Download a free report with stock ideas and industry insights for general information.
Download Free Report Now →
Basic Materials
+2.10%
Communication Services
+1.48%
Consumer Cyclical
+2.12%
Consumer Defensive
+1.59%
Energy
-2.52%
Financial Services
+1.11%
Financials
-6.05%
Healthcare
+2.12%
Industrials
-0.12%
Real Estate
+1.25%
Technology
-0.07%
Utilities
+0.57%
Note: Daily price change (%) by sector excluding stocks with +/-90% daily price change. Companies above $500 million market capitalization are considered.
Portfolio
Watchlist
Please wait processing your request...